Business Wire

Mundipharma presents wealth of data for Penthrox®▼ (methoxyflurane) at EUSEM Congress, demonstrating superiority compared to standard of care in trauma pain in adults

Share

FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLY

Mundipharma presents new data for the inhaled analgesic Penthrox ® (methoxyflurane)6 at the European Society for Emergency Medicine (EUSEM) Congress 2019, from 12–16 October. Five abstracts are being presented, advancing the understanding of the use of methoxyflurane in the treatment of moderate to severe trauma-related pain for adults in emergency settings in Europe:

MEDITA Study1 #18647: the first study to directly compare the effectiveness of methoxyflurane to standard analgesic treatment (SAT) – IV morphine for severe pain, and IV paracetamol or ketoprofen for moderate trauma pain in Italy.

  • Methoxyflurane was superior to IV morphine (severe pain) and IV paracetamol or IV ketoprofen (moderate pain) for the primary endpoint, defined as the change in pain intensity over the first 10 minutes (overall adjusted mean treatment difference: 5.94mm; 95% CI: 8.83, 3.06mm) following pain treatment administration.1
  • Methoxyflurane was rated as ‘excellent’, ‘very good’ or ‘good’ by significantly more patients in the methoxyflurane group, compared to the SAT group (72.7% vs 60.9%; p=0.001) and significantly more healthcare professionals rated the practicality of methoxyflurane as ‘excellent’, ‘very good’ or ‘good’, compared to SAT (90.3% vs 64.4%; p<0.001).1

PenASAP Study5 #19302: a placebo-controlled study comparing the effectiveness of methoxyflurane plus standard of care (SoC) analgesia vs SoC analgesia plus placebo for the management of moderate to severe trauma pain in France.

  • Results demonstrate the superiority of methoxyflurane in combination with SoC vs placebo plus SoC, in achieving pain relief for patients with moderate to severe trauma pain. For the primary endpoint, the median time to pain relief, defined as 30mm or less on the visual analogue scale, was 35 minutes in the methoxyflurane plus SoC group (p<0.001) and was not reached in the SoC plus placebo group.5

InMEDIATE Study2-4 #18659, #18660, #18661: sub-analyses from a study comparing methoxyflurane to existing SAT in acute moderate to severe trauma pain in Spain.

  • Methoxyflurane use in the elderly (at least 65 years old) provided significantly faster pain relief than SAT (time to first pain relief of 5.55 vs 12.8 minutes, and time to first meaningful pain relief of 12.57 vs 25.07 minutes), respectively.2
  • In patients with severe trauma-related pain (numerical rating scale score of 7 or more), decrease from baseline was significantly larger for methoxyflurane than SAT at all time points (3, 5, 10, 15 and 20 minutes) (p<0.001), with the largest treatment difference reported at 10 minutes.3
  • In patients with acute trauma pain (numerical rating scale score of 4 or more) who received first-step IV analgesic, the decrease from baseline was significantly larger for methoxyflurane than SAT at all time points (3, 5, 10, 15 and 20 minutes) (p<0.001), with the largest treatment difference reported at 10 minutes.4

Methoxyflurane was generally well tolerated in all the studies, with most adverse events (AEs), primarily dizziness, being mild and transient but occurring more frequently than in the comparator groups.2-6 In the PenASAP study, two severe AEs occurred in the methoxyflurane plus SoC group, including one that was assessed as treatment-related.5

“We are very excited by these data demonstrating the superiority of methoxyflurane when compared directly with standard treatment, or compared with placebo when used in addition to SoC for moderate-to-severe trauma pain, in real-world settings in European countries” said Sara Dickerson, Medical Affairs Lead for Mundipharma. “We know that trauma pain is too often undertreated, or even untreated, which can be very distressing for patients and can lead to long-term effects. Results from these studies support the use of methoxyflurane as a simple, fast and effective non-opioid treatment option for adult patients experiencing trauma pain.”

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get to your local medicines regulatory authority.

-Ends-

Notes to editors

About Penthrox® (methoxyflurane)

Penthrox is a small, light-weight, hand-held, inhaled non-opioid analgesic.6,7 It is indicated in Europe for the emergency relief of moderate to severe pain in conscious adults with trauma and associated pain.6,8 It is a self-administered analgesic (under supervision) and provides rapid pain relief within three minutes9 or six to ten inhalations.10,11 Methoxyflurane as an analgesic has been used by more than six million people over the course of 40 years, in Australia and New Zealand.12 It has an established tolerability profile and a body of supporting evidence in adult trauma pain.13,14

Mundipharma International Corporation Limited has exclusive rights to Penthrox in 40 European markets, including France, Germany, Italy and Spain, but excluding the Republic of Ireland and the United Kingdom.

PENTHROX® is a registered trade mark of Medical Developments International Limited and is used under licence.

Click here to watch an animation about the management of trauma pain in Europe: www.mundipharma.com/media_video/taking-the-pain-out-of-trauma/

About Management of Trauma Pain in the Pre-Hospital Setting

33 million people across Europe visit the hospital emergency department due to injuries every year.15 Trauma pain requires fast, effective pain relief (analgesia).7 Although inadequate pain treatment can cause clinical deterioration, pain is undertreated in both the emergency department and pre-hospital setting, and remains a significant problem.7,16 Current analgesics have limitations in pre-hospital settings and there is a need for fast-acting, non-invasive, non-narcotic analgesia.7,17

About the Mundipharma Network

Mundipharma is a global network of privately-owned independent associated companies whose purpose is to move medicine forward. With a high performing and learning organisation that strives for innovation and commercial excellence through partnerships, we successfully transformed and diversified our European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as Diabetes, Respiratory, Oncology, Pain and Biosimilars.

References

1 Serra S, Ruggiano G, Fabbri A, et al. Methoxyflurane versus standard analgesic treatment for acute trauma-related pain in the emergency setting: results of a randomised, controlled study in Italy (MEDITA). Presented at EUSEM 2019. Abstract #18647, Poster P37.

2 Capilla Pueyo R, Fernandez Alonso C, Garcia S, et al. Methoxyflurane, an efficient and well tolerated analgesic for elderly patients, compared with standard analgesic treatment: subgroup analysis of a phase IIIb randomised, controlled trial (InMEDIATE). Presented at EUSEM 2019. Abstract #18659 - OP014.

3 Fernández Alonso C, Garcia Collado S, Carballo Cardona C, et al. Low dose of inhaled Methoxyflurane: more effective and rapid-acting than standard analgesic treatment, also for severe trauma-related pain: subgroup analysis of a randomised controlled trial (InMEDIATE). Presented at EUSEM 2019. Abstract #18660 - SP090.

4 Carballo Cardona C, Capilla Pueyo R, Fernandez Alonso C, et al. Low dose of inhaled methoxyflurane is more effective with higher patient and clinician satisfaction than first-step intravenous analgesic treatment for acute trauma-related pain: subgroup analysis of a phase IIIb randomised controlled trial (InMEDIATE). Presented at EUSEM 2019. Abstract #18661 - OP015.

5 Ricard-Hibon A, Lecoules N, Savary D, et al. A randomised, double blind placebo-controlled study of methoxyflurane plus standard of care analgesia versus placebo plus standard of care analgesia for moderate to severe pain associated with trauma (The PenASAP Study). Presented at EUSEM 2019. Abstract #19302 - OP008.

6 eMC. Penthrox Summary of Product Characteristics. Available at: www.medicines.org.uk/emc/product/1939/smpc/print. Accessed October 2019.

7 Marinangeli F, Reggiardo G, Sblendido A, et al. Prospective, Multicentre Trial of Methoxyflurane for Acute Trauma-Related Pain in Helicopter Emergency Medical Systems and Hostile Environments: METEORA Protocol. Adv Ther 2018;35:2081-92.

8 Medical Developments International. ASX Announcement: Penthrox approved in another 22 European countries 2017. Available at: www.medicaldev.com/news/asx-announcement-penthrox-approved-another-22-european-countries/ Accessed: October 2019.

9 Borobia AM, Garcia Collado S, Carballo Cardona C, et al. Inhaled Methoxyflurane Provides Greater Analgesia and Faster Onset of Action Versus Standard Analgesia in Patients With Trauma Pain: InMEDIATE: A Randomized Controlled Trial in Emergency Departments. Ann Emerg Med 2019; https://doi.org/10.1016/j.annemergmed.2019.07.028

10 Coffey F, Wright J, Hartshorn S, et al. STOP!: a randomised, double-blind, placebo-controlled study of the efficacy and safety of methoxyflurane for the treatment of acute pain. Emerg Med J 2014;31:613-618.

11 Coffey F, Dissmann P, Mirza K, et al. Methoxyflurane Analgesia in Adult Patients in the Emergency Department: A Subgroup Analysis of a Randomized, Double-blind, Placebo-controlled Study (STOP!) Adv Ther 2016;33:2012-2031.

12 Porter KM, Dayan AD, Dickerson S, et al. The role of inhaled methoxyflurane in acute pain management. Open Access Emerg Med 2018;10:149-164.

13 Grindlay J, Babl FE. Efficacy and safety of methoxyflurane analgesia in the emergency department and prehospital setting. Emerg Med Australas 2009;21(1):4-11.

14 Jephcott C, Grummet J, Nguyen N, et al. A review of the safety and efficacy of inhaled methoxyflurane as an analgesic for outpatient procedures. Br J Anaesth 2018;120(5):1040-1048.

15 Eurosafe. Injuries in the European Union: 2013-2015. Available at: www.eurosafe.eu.com/uploads/inline-files/IDB%202013-2015_suppl%20to%206th%20edition%20Injuries%20in%20the%20EU.pdf. Accessed October 2019.

16 Berben SA, Meijs TH, van Dongen RT, et al. Pain prevalence and pain relief in trauma patients in the Accident & Emergency department. Injury 2008;39:578-585.

17 Sinatra R. Causes and Consequences of Inadequate Management of Acute Pain. Pain Med 2010;11:1859-1871.

MBL/PROX-19078a Date of preparation: OCTOBER 2019

Contact information

Cendrine Banerjee-Quetel
Mundipharma International Limited
Cendrine.Banerjee-Quetel.external@mundipharma.com
Tel: +44 (0) 1223 393 009

Eleanor Craven
Makara Health
eleanor@makarahealth.com
Tel: +44 (0) 2381 247 327

To arrange an interview with a spokesperson, please contact Makara Health Communications in the first instance, using the contact details above.

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

A Better Alternative to Banking - ClubSwan.com27.1.2020 12:00:00 EETPress release

ClubSwan.com, the leader in membership driven financial solutions, further expands its innovative alternative banking capabilities to key global markets. As traditional financial institutions continually struggle to provide innovative and meaningful ways to bring value to individual and corporate customers and as digital assets/crypto currencies are experiencing global growth, ClubSwan.com continues to evolve to meet the efficiencies and demands that these new assets and our customers require and to which traditional banks have no answer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200127005046/en/ Instead, closed bank accounts, rejected transactions, crippling delays with customers receiving their funds (if at all) are all the norm with traditional banks. To add to this dilemma, the availability of trustworthy solutions where customers have peace of mind for both crypto assets and traditional currencies have been non-exi

GSMA Recognizes Turkcell and P.I. Works for the Value of AI Based Network Automation27.1.2020 10:00:00 EETPress release

Turkcell and P.I. Works have been recognized by GSMA Future Networks Programme for achieving exceptional efficiency gains in network operations and ensuring superior customer experience. P.I. Works and Turkcell have successfully shown that the AI based, service aware network automation delivered stronger improvements as compared to conventional automation solutions. The details of the deployed solutions and their benefits are provided in a joint white paper authored by GSMA, Turkcell and P.I. Works under GSMA’s Future Networks Programme. To read the white paper please visit: https://www.gsma.com/futurenetworks/wiki/case-study-ai-use-cases-in-service-assurance/ GSMA Future Networks Programme intends to help operators share best practices and discover new opportunities that will enable them to reduce operational and capital expenditures. Given the success of the project, GSMA invited Turkcell and P.I. Works to join the program and provide insights for the AI-based, Service Aware Automate

Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint27.1.2020 10:00:00 EETPress release

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced positive topline results from the pivotal phase 2 DESTINY-Gastric01 trial of DS-8201, a HER2 directed antibody drug conjugate (ADC), in patients with HER2 positive unresectable or metastatic gastric or gastroesophageal junction cancer that had progressed following two or more treatment regimens including trastuzumab and chemotherapy. The trial met its primary endpoint, achieving a statistically significant and clinically meaningful improvement in objective response rate (ORR), as assessed by an independent review committee, in patients treated with DS-8201 versus investigator’s choice of chemotherapy (irinotecan or paclitaxel monotherapy). DS-8201 also showed a statistically significant and clinically meaningful improvement in overall survival (OS), a key secondary endpoint. The safety profile observed for DS-8201 in DESTINY-Gastric01 was consistent with previous clinical trials. These results c

HighRes Biosolutions and Novo Nordisk partner to transform drug discovery in automated Lab of the Future24.1.2020 17:00:00 EETPress release

HighRes Biosolutions and Novo Nordisk A/S today announced that they will collaborate to design a state-of-the-art robotic platform for high-throughput biologics engineering and characterisation. The integration of a multi-system robotics platform with sophisticated software control architecture will enable a digital transformation and accelerated discovery for Novo Nordisk’s peptide and large molecule therapeutics research. “In order to maintain our leadership within biologics engineering we are investing in a fully automated and digital design platform. This investment is linked to our build-up in AI and advanced analytics and demonstrates Novo Nordisk’s commitment as a world leading biologics research company,” said Lars Fogh Iversen, senior vice president, Global Research Technologies, Novo Nordisk. The platform will comprise several highly automated and integrated cells for production, characterisation and functional analysis of thousands of biologic compounds every month. Its scop

Conquest Invests in 5 Greenfield Onshore Wind Parks Totalizing 43MW in the Flanders Region24.1.2020 15:37:00 EETPress release

Conquest, acting through the Conquest Sustainable Infrastructure fund, announced the transaction was closed after an exclusive agreement had been reached with ENGIE Electrabel. Conquest acquires 51% of a portfolio expected to provide 111 GWh per annum of renewable power representing the annual electricity consumption of about 32,000 Belgian homes from early 2021 onwards. The projects benefit from 15 to 20-year green certificates local remuneration schemes, and thus generate yearly secured revenues. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200124005221/en/ Credit: Electrabel While the energy and digital transitions continue to drive the infrastructure sector, Conquest keeps building its diversified sustainable real asset portfolio in Western European markets. The success lies in years of collaboration and long-lasting partnerships with fellow industry experts who can notably facilitate access to new growth opportunities

Fluence Expands EMEA Footprint with Horticulture Partners in Papenburg, Germany24.1.2020 14:00:00 EETPress release

Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and agriculture production, announced today it is expanding its presence in the Emsland region of Germany through partnerships with growers and other horticulture specialists operating out of Papenburg. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200124005109/en/ Friedrich Schulz’s 5.5 hectare farm—which grows herbs year-round in addition to lettuce, peppers and chives—utilizing VYPR 2p fixtures. (Photo: Business Wire) Given Papenburg’s decades-long history of attracting horticulture experts, Fluence’s innovative lighting solutions for horticulture are a natural fit for the region’s tomato, cucumber, leafy greens and herb growers. Forging connections with Papenburg’s horticultural leaders Elektro Evers, an engineering firm specializing in greenhouse technology, is Fluence’s exclusive systems integrator

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom